Economic Value of Lost Productivity Attributable to Human Papillomavirus Cancer Mortality in the United States

Objectives

To estimate years of potential life lost (YPLL) and present value of future lost productivity (PVFLP) associated with premature mortality due to HPV-attributable cancers, specifically those targeted by nonavalent HPV (9vHPV) vaccination, in the United States (US) before vaccine use.

Methods

YPLL was estimated from the reported number of deaths in 2017 due to HPV-related cancers, the proportion attributable to 9vHPV-targeted types, and age- and sex-specific US life expectancy. PVFLP was estimated as the product of YPLL by age- and sex-specific probability of labor force participation, annual wage, value of non-market labor, and fringe benefits markup factor.

Results

An estimated 7,085 HPV-attributable cancer deaths occurred in 2017 accounting for 154,954 YPLL, with 5,450 deaths (77%) and 121,226 YPLL (78%) attributable to 9vHPV-targeted types. The estimated PVFLP was $3.3 billion for cancer deaths attributable to 9vHPV-targeted types (86% from women). The highest productivity burden was associated with cervical cancer in women and anal and oropharyngeal cancers in men.

Conclusions

HPV-attributable cancer deaths are associated with a substantial economic burden in the US, much of which could be vaccine preventable.

AuthorsM Priyadarshini, VS Prabhu, SJ Snedecor, S Corman, BJ Kuter, C Nwankwo, D Chirovsky, E Myers
JournalFrontiers in Public Health
Therapeutic AreaOncology
Service AreaModeling & Meta-Analysis
Year2021
LinkClick Here

Share this post